Please assess the completion status of the following clinical trial:

Trial Title: Certolizumab Pegol for Treatment of Adult Greek Patients With Moderate to Severe Crohn's Disease Who Failed Infliximab

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~• Adult men and women with Crohn's disease previously responsive to infliximab who became non-responsive or intolerant~Exclusion Criteria:~* Symptomatic obstructive intestinal strictures~* Bowel resection within 4 weeks~* Current total parenteral nutrition~* Short bowel syndrome~* Concomitant disease or pathological condition that could interfere with Crohn's disease or to be harmful for the well being of the patient.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Certolizumab pegol (Type: EXPERIMENTAL): certolizumab pegol 400 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).